




recomLine HEV IgG/IgM

Strip immunoassay with recombinant antigens for the detection of IgG or IgM antibodies against Hepatitis E virus (HEV) in human serum or plasma

Hepatitis E virus (HEV) is one of the leading causes of faecal-orally acquired hepatitis worldwide, usually resulting from contaminated drinking water. In developed countries, hepatitis E is usually transmitted through infected pork, which was not sufficiently cooked. HEV can be transmitted through blood products, blood transfusions and organ donation. In Europe most cases of hepatitis E are caused by the HEV genotype 3.

The HEV infection usually remains asymptomatic. Acute hepatitis E is an illness with a clinical presentation comparable to hepatitis A. Typical signs of hepatitis E include flu-like symptoms, vomiting, diarrhoea, fever, arthralgia and headache usually associated with a rise in liver enzyme values. Cholestatic jaundice that develops during the course of disease can persist for several weeks. HEV infection is usually self-limiting. In endemic regions in a high percentage of cases HEV infections during pregnancy follow a fulminant course, accompanied by a high mortality rate of approx. 20%. In males and non-pregnant females the mortality rate is 0.5% - 4.0%.

The *recomLine* HEV IgG/IgM uses purified recombinant antigens, thus reproducibly ensuring high sensitivity and specificity. The selection of homologous proteins from two different genotypes (genotype 1 and genotype 3) facilitates a high sensitivity also in non-endemic areas with a high percentage of autochthonous cases of hepatitis E.



Product advantages


- Recombinant antigens
 - High sensitivity and specificity
 - Easy and clear interpretation due to easy to read bands
 - Homologous antigens of two different genotypes: genotype 1 and genotype 3
 - Detection of all four HEV-genotypes
- Easy test procedure; automation possible
- Easy and objective evaluation and documentation by *recomScan* software
- Test procedure and reagents identical in all MIKROGEN strip tests - reagents exchangeable
- Separate detection of IgG- and IgM-antibodies - conjugate control on each strip
- Safe evaluation due to test strip specific cutoff control
- CE label: The *recomLine* HEV test meet the high standard of EC directive 98/79/EC on in vitro diagnostic medical devices
- Application for confirmation as well as for screening

Recombinant HEV antigens

| Antigen | Location | Origin |
|---------|--|------------------------|
| O2N | N-terminal part of ORF* 2 protein (HEV capsid-protein) | Genotype 1, Genotype 3 |
| O2M | Middle part of ORF* 2 protein (HEV capsid-protein) | Genotype 1 |
| O2C | C-terminal part of ORF* 2 protein (HEV capsid-protein) | Genotype 1, Genotype 3 |
| O3 | ORF* 3 protein of HEV | Genotype 1, Genotype 3 |

*ORF = open reading frame

Test Principle and Procedure



- 1st Incubation** A test strip loaded with HEV antigens is incubated with diluted serum or plasma in a dish for **1 hour**.
wash 3 times
- 2nd Incubation** Peroxidase conjugated anti-human antibodies (IgG or IgM specific) are added. Incubate for **45 minutes**.
wash 3 times
- Color reaction** **8 minutes** after addition of the coloring solution, insoluble colored bands develop at the sites on the test strips adhered by antibodies.

Evaluation

Sensitivity

| | HEV acute sera ¹ (n = 89) | |
|-------------|--------------------------------------|--------|
| | IgG | IgM |
| negative | 3 | 6 |
| borderline | 1 | 0 |
| positive | 85 | 83 |
| Sensitivity | 96.6 % | 93.3 % |

¹ Charité, University Hospital, Berlin, Germany

Specificity

| | HEV seronegative | |
|-------------|---------------------------|----------------------------|
| | IgG ¹ (n = 69) | IgM ² (n = 256) |
| negative | 67 | 248 |
| borderline | 0 | 1 |
| positive | 2 | 7 |
| Specificity | 97.1 % | 96.9 % |

¹ Blood donor sera have been concordantly evaluated as negatives in *recomWell* HEV IgG and another HEV ELISA IgG.

² 156 sera from patients with clinical suspicion of non-E hepatitis; Serologically defined by *recomWell* HEV IgM ELISA, by another ELISA, and a confirmatory assay; positive for either HBs-IgM-, HAV-IgM-, CMV-IgM- Parvo-IgM antibodies, HCV-IgG antibodies; and 100 negative blood donors.

Seroprevalence

| | Blood donors (Bavarian Red Cross) (n= 100) | | Hepatitis A, B, C positive samples ¹ (n = 49) | |
|------------|--|-----|---|-----|
| | IgG | IgM | IgG | IgM |
| negative | 69 | 99 | 44 | 49 |
| borderline | 0 | 0 | 1 | 0 |
| positive | 31 | 1 | 4 | 0 |
| | 31 % | 1 % | 10.6 % | 0 % |
| | Seroprevalence | | Reactivity rate | |

¹ Positive for (and/ or in each case) HBs-, HBe-antigen, HBs-IgM-, anti-HBs-, anti-HBc-, anti-HCV, HAV-IgM-, HAV-IgG-antibodies

Article-No

- 5072 **recomLine HEV IgG/IgM**
Reagents for 20 determinations
- 5070 **recomLine HEV IgG/IgM**
Reagents for 100 determinations

Storage

+2°C - +8°C